Sun Pharma and Organon Announce $11.75 Billion Merger, Marking a Significant Milestone in India's Global Acquisition Strategy

Indian Companies' Global Ambitions on Display with Sun Pharma's $11.75-Billion Acquisition

The proposed acquisition of US-based Organon & Co by Sun Pharmaceutical Industries for $11.75 billion highlights the growing global ambitions of Indian companies. This record-breaking pharma deal underscores a broader trend in Indian boardrooms, where cash-rich companies, backed by stronger balance sheets, are hunting for global scale, technology, and market.

The Organon deal, one of the largest outbound transactions by an Indian company, comes on the back of a sharp surge in overseas M&A activity. According to LSEG data, India Inc's outbound deal value rose to $16.8 billion in 2025 from $7.7 billion in the previous year, marking the highest annual activity in nearly a decade.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The surge in outbound M&A activity has been driven by stronger corporate balance sheets, access to sophisticated financing structures, and increasing participation from financial sponsors. Indian companies are increasingly using acquisitions to move up the value chain by buying intellectual property, R&D capabilities, established brands, and distribution networks that would take years to build organically.

The Sun Pharma-Organon transaction, which is expected to be completed by early 2027, shows that after a long period of cautious approach on overseas acquisitions, Indian businesses are back to pursuing large global acquisitions to accelerate strategic transformation. The acquisition of Organon provides the company immediate scale in key global markets and strengthens Sun's portfolio in women's health and specialty segments, areas that offer relatively stable cash flows and differentiation compared to commoditised generics.

Post-integration, the combined Sun-Organon entity is expected to generate $12.4 billion in annual revenue, almost double Sun Pharma's standalone $6.2 billion revenue in FY25. The combined EBITDA is expected to rise to about $3.7 billion.

The surge in outbound M&A activity has also been driven by favourable market conditions. Indian corporates, after a decade of deleveraging, are now better positioned to deploy capital overseas. Strong equity markets and rising private equity participation have further boosted confidence, enabling even mid-sized and promoter-led companies to pursue international acquisitions.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

However, bankers caution that while the momentum is likely to continue, dealmaking will remain sensitive to external factors such as geopolitical risks, currency volatility, and valuation mismatches. Volatile stock markets and corrections in valuations amid the geo-political conflict in West Asia may also dent Indian companies' confidence to pursue ambitious acquisitions.

Sun Pharma on April 27 announced the biggest acquisition ever by an Indian pharma player, agreeing to acquire US-listed Organon & Co in an all-cash deal valued at about $11.75 billion. The move dramatically reshapes Sun's global scale and therapeutic footprint, as it looks to accelerate its transformation into a large, diversified global drugmaker by securing growth engines beyond traditional generics.